Respiratory Physiotherapy for Patients With Bronchiectasis

Bronchiectasis Adult

E-FACED, bronchiectasis, pulmonary rehabilitation, respiratory muscle training, breathing exercise, computed tomography, microbiology, respiratory physiotherapy, airway clearance techniques

Study design: observational, retrospective Population: 270 patients diagnosed with bronchiectasis (BX) treated at the Respiratory Physiotherapy Unit of the Rehabilitation Service of the A Coruña and Cee Health Area. Objective: To determine the profile of patients diagnosed with BX (not due to cystic fibrosis) treated at the Respiratory Physiotherapy Unit of the Rehabilitation Service of the A Coruña and Cee Health Area between 1 January 2022 and 1 March 2026. Hypotheses: * Main hypothesis These patients exhibit a high degree of heterogeneity. It is expected that the characterisation of these patients' clinical and functional variables-such as lung function, respiratory muscle strength, frequency of exacerbations and chronic bronchial colonisation by microorganisms-will enable the identification of distinct patterns within this population. * Secondary hypotheses * Patients with a higher burden of comorbidity have a poorer clinical prognosis and make greater use of resources. * Respiratory rehabilitation interventions will lead to improvements in these variables. * The combined analysis of clinical, functional and microbiological variables will enable the identification of patient profiles at higher risk. Applicability: The study will provide specific and up-to-date knowledge, enabling the optimisation of follow-up strategies and the adaptation of RF interventions to patients' actual needs, thereby improving the quality of care. The results will contribute to the formulation of new research questions. Ethical considerations: The information will be processed in a pseudonymised manner, ensuring the confidentiality and security of the data in accordance with the General Data Protection Regulation. Given the retrospective nature of the study and compliance with the established pseudonymisation requirements, an exemption from informed consent will be requested from the Ethics Committee, in accordance with Additional Provision 17 of Organic Law 3/2018, relating to the processing of health data for research purposes, justified by the minimal risk involved and the privacy controls in place for the information. Estimated duration: 9-10 months from the date of approval by the Ethics Committee, including data collection, statistical analysis and the dissemination of results. Budget: No external funding required. Conclusion: This project will provide detailed and rigorous clinical information on patients with bronchiectasis in real-world clinical practice.

The applicability of the study is based on the following aspects: 1. Generation of real-world data The retrospective analysis will provide information derived from routine clinical practice, complementing the evidence from clinical trials and providing data representative of the healthcare context within the Galician health system. 2. Potential improvement in clinical practice The identification of clinical profiles, associated comorbidities and variables related to disease progression may help to optimise clinical follow-up models, facilitate risk stratification and promote more personalised care for patients with BX. 3. Organisational impact and healthcare efficiency Understanding the characteristics and care needs of this cohort will help to guide future organisational strategies, improve resource planning and facilitate interventions aimed at reducing exacerbations, hospitalisations and avoidable healthcare utilisation. 4. Basis for future lines of research The results obtained may generate hypotheses for subsequent prospective studies and multicentre projects, contributing to the development of clinical research into chronic respiratory conditions within the public healthcare system. 5. Ethical proportionality and risk minimisation As this is a single-centre, retrospective, observational study based exclusively on the review of existing clinical data, with no intervention in patients' care or modification of their clinical management, the risk to participants is minimal. The data will be processed in a pseudonymised form, ensuring confidentiality in accordance with Regulation (EU) 2016/679 and current Spanish legislation on personal data protection and biomedical research. Overall, the project has high clinical and organisational applicability, as it generates knowledge that is directly transferable to clinical practice, with an appropriate risk-benefit balance and clear social value aimed at improving healthcare for patients with BX. METHODOLOGY Scope of the study The study population will consist of 270 patients diagnosed with BX who are being treated at the Respiratory Rehabilitation Unit of the Rehabilitation Service in the A Coruña and Cee area, referred from the Pulmonology Department at HUAC. Data will be collected retrospectively through a review of medical records. Study period The period over which data will be collected will run from 1 January 2022 to 1 March 2026. Sample size A sample size of 270 patients will allow the characteristics of the cohort to be estimated with a 95% confidence level and a precision of ±11%, assuming an expected prevalence of 50%, thereby ensuring a sufficient sample size. A follow-up loss rate of 10% has been estimated. Sample selection Non-probabilistic consecutive sampling will be used, including all patients who meet the inclusion criteria during the specified period. Given the retrospective design, available medical records will be systematically reviewed to ensure that all eligible cases are included in the analysis. LIMITATIONS This study has a number of limitations inherent to its methodological design which must be taken into account when interpreting the results: 1. Retrospective design 2. As this is a retrospective observational study based on the review of medical records, the information available will depend on the quality and completeness of the existing clinical records; data may be incomplete or not systematically recorded. 3. Possible reporting bias Data collection from healthcare records may lead to variability in the measurement or documentation of certain clinical, functional or microbiological variables, which could introduce reporting bias. 4. Single-centre study The single-centre nature of the study may limit the external generalisability of the results to other populations or healthcare settings with different characteristics. However, it allows for greater consistency in diagnostic criteria and in the clinical practice applied. 5. Lack of experimental control Given the observational design, it is not possible to establish causal relationships between the variables analysed; the study is limited to identifying clinical associations. 6. Missing data It is to be expected that some variables will have missing values due to the retrospective nature of the study. This issue will be addressed through a case-n-necessary analysis, describing the proportion of missing data for each variable analysed. 7. Variability in clinical follow-up The duration of follow-up and the frequency of assessments may vary between patients depending on standard clinical practice, which may influence the comparison of long-term outcomes. Despite these limitations, the study provides relevant information derived from real-world clinical practice, which is a strength for understanding the characteristics and clinical course of patients with BX in the usual clinical setting.

No related papers found yet.

None listed

Spain